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Abstract
Grade IV glioma is the most common and aggressive primary brain tumour. Gross total resection with 5-aminolevulinic 
acid (5-ALA) guided surgery combined with local chemotherapy (carmustine wafers) is an attractive treatment strategy in 
these patients. No previous studies have examined the benefit carmustine wafers in a treatment programme of 5-ALA guided 
resection followed by a temozolomide-based chemoradiotherapy protocol. The objective of this study was to examine the 
benefit of carmustine wafers on survival in patients undergoing 5-ALA guided resection. A retrospective cohort study of 260 
patients who underwent 5-ALA resection of confirmed WHO 2007 Grade IV glioma between July 2009 and December 2014. 
Survival curves were calculated using the Kaplan–Meier method from surgery. The log-rank test was used to compare survival 
curves between groups. Cox regression was performed to identify variables predicting survival. A propensity score matched 
analysis was used to compare survival between patients who did and did not receive carmustine wafers while controlling for 
baseline characteristics. Propensity matched analysis showed no significant survival benefit of insertion of carmustine wafers 
over 5-ALA resection alone (HR 0.97 [0.68–1.26], p = 0.836). There was a trend to higher incidence of wound infection in 
those who received carmustine wafers (15.4 vs. 7.1%, p = 0.064). The Cox regression analysis showed that intraoperative 
residual fluorescent tumour and residual enhancing tumour on post-operative MRI were significantly predictive of reduced 
survival. Carmustine wafers have no added benefit following 5-ALA guided resection. Residual fluorescence and residual 
enhancing disease following resection have a negative impact on survival.
Keywords Neurosurgery · Glioma · 5-Aminolevulinic acid · Carmustine
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Introduction
WHO Grade IV glioma is the most common and aggressive 
primary brain tumour and presents amongst the most formi-
dable challenges of any cancer. Each year in the UK ~ 4300 
new cases of brain or central nervous system (CNS) cancers 
are diagnosed, around 7 per 100,000 population. Although 
brain tumours account for < 2% of all primary tumours they 
are responsible for 7% of the years of life lost from cancer 
before age 70 (ONS 2006 Series MB1 No. 34). If the burden 
of disease is considered in terms of the average years of life 
lost per patient, brain tumours are one of the most lethal 
cancers with over 20 years of life lost [1].
Surgery remains a mainstay of treatment and is essen-
tial in establishing a diagnosis. As surgical techniques have 
improved, the importance of obtaining a gross total resection 
is increasingly recognized and is being incorporated into 
European guidelines [2, 3]. Prospective cohort data suggest 
that radical resection, defined by the absence of post-oper-
ative contrast enhancing disease, improves survival (over 9 
months) [4], that gross total resection (GTR) but not incom-
plete resection of glioblastoma prolongs survival (6 months) 
in the era of radiochemotherapy [5] and also that multiple 
resections for patients with glioblastoma can prolong sur-
vival [6].
Complete resection of contrast enhancing disease is only 
achieved in a minority of patients because identifying the 
margin between tumour and adjacent brain intraoperatively 
is frequently challenging. 5-aminolevulinic acid (5-ALA) 
is a heme precursor that after oral administration results in 
accumulation of porphyrins in epithelial and neoplastic cells, 
including malignant glioma. Under ultraviolet light from an 
operating microscope tumour tissue is distinctly fluorescent 
compared with surrounding white matter and provides the 
surgeon with real-time intraoperative guidance during resec-
tion [7]. A phase III randomised controlled trial has shown 
that 5-ALA guided resection of malignant glioma is associ-
ated with a significant increase in the proportion of patients 
where complete resection of enhancing tumour is achieved 
and improved progression-free survival at 6 months [8].
Local chemotherapy with biodegradable carmustine 
impregnated wafers inserted into the surgical resection cav-
ity is an attractive strategy to directly deliver an active agent 
into the brain interstitium and circumvent the limited bio-
availability and the adverse effects associated with systemic 
administration [9]. Although two randomised trials pointed 
towards a treatment effect of carmustine wafers for newly 
diagnosed grade IV glioma [10, 11], these were shortly fol-
lowed by clear evidence of significantly improved survival 
with combined radiotherapy and systemic temozolomide. In 
this context, together with improved surgical resection strat-
egies, the efficacy of carmustine wafers remains unproven.
The objective of this study was to examine the additional 
benefit of carmustine wafers on survival in patients undergo-
ing 5-ALA guided tumour resection and factors correlated 
with survival.
Methods
Data collection
Since July 2009 all patients who receive 5-ALA fluores-
cence guided resection and/or carmustine wafers (Gliadel) 
implants have been prospectively recorded at our unit. 
From this database we selected all patients who underwent 
primary resection of a radiologically suspected malignant 
glioma and in whom the histopathological analysis subse-
quently confirmed a WHO 2007 grade IV glioma, operated 
on between July 2009 and December 2014.
Electronic health records were accessed to retrieve addi-
tional data regarding the surgical procedure, pathological 
findings, and adjuvant chemo- and radiotherapy the patient 
received. Our unit policy is to obtain post-operative con-
trast enhanced cerebral magnetic resonance imaging (MRI) 
within 72 h from surgery. The neuroradiologists’ reports 
were reviewed for each patient in the cohort to determine 
whether any contrast enhancing tumour remained follow-
ing surgery.
The location of each tumour was determined following 
review of relevant neuroradiology reports, operative notes, 
and preoperative stealth MRIs. In the event that a tumour 
extended into multiple regions (e.g. parieto-occipital), it was 
counted in the total for both involved regions. Tumour size 
was defined by measuring the maximum axial dimension on 
preoperative scans. Measurements were corroborated with 
neuroradiology reports, whenever possible, and placed into 
RTOG size groups.
The decision of intention to insert carmustine wafers was 
made pre-operatively and then confirmed once the intraoper-
ative frozen section indicated a high-grade glioma and there 
were no contraindications such as a wide opening of the lat-
eral ventricle. Between four and eight wafers were inserted.
Post-operative oncology treatment, if received, was clas-
sified as either palliative: radiotherapy (typically 30 Gy in 
six fractions), or radical radiotherapy (60 Gy in 30 frac-
tions), or radical chemo-radiotherapy i.e. radiotherapy com-
bined with concomitant and/or adjuvant temozolomide as 
per the Stupp protocol [4].
Current status of patients and dates of death were ascer-
tained through the NHS national tracing service on 01 Janu-
ary 2017 i.e. a minimum of 2 years after diagnosis. The 
project was registered and approved with the local audit 
department prior to data collection (local audit number PRN 
4507).
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IDH1 and IDH2 mutation analysis and MGMT 
methylation analysis
Immunohistochemistry for the protein product of mutant 
IDH1 R132H was performed on deparaffinised sections 
after heat-induced antigen retrieval. In appropriate cases 
that did not have the common mutation, tumour samples 
were submitted for next-generation sequencing to look for 
rarer IDH1 mutations on exon 4, codon 132, and muta-
tions of IDH2 on exon 4, codon 172. To determine MGMT 
promoter methylation status, tumour DNA was extracted 
and bisulphite-converted. The MGMT promoter methyla-
tion was determined by pyrosequencing of four CpG sites 
(CpGs 76–79) in exon 1 of the MGMT gene using the 
CE-Marked Therascreen MGMT Pyro Kit on a Pyromark 
Q24 System (Qiagen). A cut-off of 10% methylation for 
the four CpG sites is used to assign a glioma as methylated 
or unmethylated based on published data [12–14].
Statistical analysis
The effect of 5-ALA guidance on extent of resection was 
measured as whether there was residual enhancing tumour 
on early post-operative MRI. Comparison was made using 
the standard chi-squared test between patients with or 
without 5-ALA guided resection.
Overall survival curves were calculated using the 
Kaplan–Meier method from the date of surgery until date 
of death from all causes. The log-rank test was used to 
compare survival curves between carmustine versus no 
carmustine. Cox proportional hazards regression was 
performed to investigate independent factors predicting 
survival.
To compare survival between patients who did and did 
not receive carmustine wafers while controlling for differ-
ences in their baseline characteristics a propensity score 
matched analysis was also conducted [15]. The propensity 
score was calculated with a logistic regression of age, sex, 
tumour size, presence of residual (5-ALA) fluorescence at 
the end of resection, and whether the lateral ventricle had 
been opened during the procedure. Control (i.e. no carmus-
tine wafers) patients were then matched to patients who 
received carmustine wafers with an optimal matching pro-
cedure and caliper width of 0.1, without replacement.
The independent effect on survival of variables such as 
carmustine wafers and residual enhancement on post-oper-
ative MRI was further estimated using standardised inverse 
probability weighting to adjust the respective survival 
curves. The weighting was calculated as the actual prob-
ability of group assignment divided by the predicted group 
assignment based on a logistic regression of other pre- and 
post-operative variables.
All analysis was carried out in R (v. 3.3.0; http://www.r-
project.org) using the stats, survival, and MatchIt packages. 
Statistical significance level was set at p < 0.05.
Results
5‑ALA and carmustine wafers
A total of 260 patients underwent primary 5-ALA guided 
resection of a confirmed grade IV glioma between 2009 
and 2014; 78 (30%) of these also received carmustine wafer 
implants. The age, sex, and pathology of patients in each 
group were similar. However, tumour size (RTOG classi-
fication), completeness of resection based on residual fluo-
rescence and MRI, and the oncological treatment patients 
received following surgery was significantly different 
between the groups (Table 1). The variation in post-opera-
tive oncological management reflects the real-world nature 
of the patient cohort consistent with a surgical study. NICE 
guidelines permit RT/TMZ (Stupp protocol) for patients 
with PS 0–1 so post-operative changes may alter subsequent 
treatment. There was an association between tumour size 
and presence of residual enhancement on post-operative 
MRI (RTOG I: 32.4% vs. RTOG II: 45.5%, p = 0.044). In 
addition, there was a trend to higher incidence of wound 
infection requiring revision surgery in the patients who 
received carmustine wafers (12/78 [15.4%] vs. 13/182 
[7.1%], p = 0.064).
Unadjusted comparison of survival between patients who 
received carmustine and those who did not, found 6 month 
survival was not significantly different (carmustine vs. no 
carmustine; 16.7 vs. 24.2%, p = 0.239). There was a signifi-
cant difference at 12 months (35.9 vs. 54.4%, p = 0.009) but 
this did not persist at 24 months (78.2 vs. 82.4%, p = 0.338) 
and overall comparison of survival curves similarly found no 
significant difference (median 14.7 vs. 11.0 months; hazard 
ratio [95% CI] 0.81 [0.54–1.09], p = 0.13; Fig. 1a).
We then calculated a propensity score for the use of car-
mustine wafers for each patient based on pre-implantation 
factors comprising age, sex, tumour size, presence of resid-
ual fluorescent tumour, and whether the lateral ventricle was 
opened. This allowed 76 patients who received carmustine 
wafers to be matched to the same number of patients with 
similar pre-implantation features who did not receive car-
mustine wafers. Comparison of survival between these 
matched groups found no significant difference in overall 
survival (median 14.2 vs. 14.3 months; HR 1.10 [0.79–1.53], 
p = 0.59; Fig. 1b).
To examine the independent effects of both pre- and 
post-operative factors on survival a Cox proportional 
hazards regression model was constructed. Age, tumour 
size, residual intraoperative fluorescent tumour, residual 
276 Journal of Neuro-Oncology (2018) 136:273–280
1 3
enhancing tumour on early post-operative MRI, and adju-
vant treatment were identified as significantly associated 
with survival, whereas use of carmustine wafers was not 
(Table 2).
Correspondingly, survival curves adjusted for both 
pre- and post-operative factors, namely age, sex, tumour 
size, residual fluorescence, residual enhancing tumour on 
MRI, and adjuvant treatment, using standardised inverse 
variance weighting were essentially indistinguishable 
between the group of patients who received carmus-
tine wafers and those who did not (median 12.3 vs. 12.6 
months; HR 1.12 [0.85–1.50], p = 0.44; Fig. 1c).
Table 1  Details of the patient cohort
5-ALA 5-aminolevulinic acid, RT radiotherapy, RTOG radiation ther-
apy oncology group, GBM glioblastoma multiforme, GBMO GBM 
with oligodendroglial component, GBMP GBM with primitive neu-
roectodermal tumour (PNET) differentiation, GS gliosarcoma
5-ALA; no wafers 5-ALA; 
with 
wafers
N 182 78
Age (years; median 
[IQR])
63 [10] 61 [14] P = 0.07
Sex (% male) 65.4 70.5 P = 0.50
RTOG class (%) P = 0.043
 I 52.2 66.7
 II 47.8 33.3
Location P = 0.240
 Frontal 31.3 32.1
 Temporal 43.4 33.3
 Parietal 27.5 41.0
 Occipital 11.0 14.1
Residual disease (%)
 Fluorescence 45.2 25 P = 0.04
 MRI 45.3 29.9 P = 0.10
Wound infection (%) 7.1 15.4 P = 0.06
Pathology (%) P = 0.16
 GBM 78 69
 GBMO 17 26.9
 GS 2.7 3.8
 GBMP 2.2 0
Post-operative treatment 
(%)
P = 0.0009
 None 20 11.5
 Palliative RT (30 Gy) 28.3 10.3
 Radical RT (60 Gy) 3.3 5.1
 Chemotherapy + RT 
(60 Gy)
48.3 73.1
 Repeat resection (%) 2.2 5.1 P = 0.25
Fig. 1  Comparison of survival for patients treated with or without 
carmustine wafers. Kaplan–Meier survival curves for patients hav-
ing 5-ALA guided resection without carmustine wafers (No CW) and 
5-ALA resection with carmustine wafers (CW). a Unadjusted analysis 
of the two patient groups. b Groups matched for baseline covariates 
by propensity score (see text for details). c Survival curves adjusted 
for baseline covariates and post-operative treatment by inverse prob-
ability weighting. HR hazard ratio for the log-rank test
277Journal of Neuro-Oncology (2018) 136:273–280 
1 3
Residual tumour
The Cox regression analysis showed that both intraopera-
tive residual fluorescent tumour and residual enhancing 
tumour on post-operative MRI were significantly predictive 
of reduced overall survival (Table 2). To further demonstrate 
this, survival curves for patients with or without residual 
enhancing tumour on MRI adjusted for age, sex, tumour 
size, insertion of carmustine wafers, and adjuvant therapy, 
were constructed and revealed significantly better survival 
for patients without residual tumour (median 13.5 vs. 10.5 
months; HR 0.73 [0.56–0.95], p = 0.022; Fig. 2).
Importantly, though the presence of residual 5-ALA fluo-
rescence and residual contrast enhancement on early MRI 
were consistent in 154 (59.3%) of patients, in a substantial 
proportion 106 (40.7%) the intraoperative and post-operative 
assessment of residual disease differed (Table 3).
MGMT and IDH‑1 status
Routine clinical evaluation of MGMT methylation status and 
IDH-1/2 mutation were available for 226 (111 methylated) 
and 128 (10 mutated) patients, respectively. Surprisingly, 
MGMT methylation was not significantly associated with 
survival on univariate analysis (HR 1.06 [0.81–1.39]) and 
in the multivariable Cox model (Table 2).
For the ten patients with the IDH-1/2 mutation median 
survival was markedly longer than for the wildtype patients 
(median 24.1 vs. 12.6 months, log-rank test p = 0.067, likeli-
hood ratio test p = 0.045). The borderline statistical signifi-
cance presumably reflects the low number of patients with 
the mutation in this study.
Discussion
This study has shown that implantation of carmustine wafers 
does not have an independent effect on survival in patients 
undergoing 5-ALA guided resection of glioblastoma. In con-
trast, extent of resection, as evidenced by residual 5-ALA 
fluorescence and/or residual contrast enhancement on MRI, 
was found to be an independent prognostic factor for overall 
survival.
Although the raw unadjusted analyses pointed to a poten-
tial benefit of carmustine wafers, when preoperative factors 
including age, size of tumour, and residual fluorescence, 
were appropriately controlled for there was no demonstrable 
effect on outcome. Additional adjustment for post-operative 
factors, including radiological residual tumour and adjuvant 
therapy, also did not reveal any benefit of carmustine wafers. 
Table 2  Cox-regression analysis (n = 248)
Bold indicate  P values of < 0.05
Abbreviations as in Table 1
Factor Coefficient P value
Age (per year) 1.02 0.009
Sex (female vs. male) 1.03 0.86
Carmustine wafers 1.28 0.13
Residual
 Fluorescence 1.54 0.004
 MRI 1.70 0.0003
Infection 1.33 0.21
Pathology (vs. GBM)
 GBMO 1.26 0.17
 GS 0.90 0.80
 GBMP 1.22 0.71
MGMT methylation positive (n = 128) 1.30 0.24
IDH1 (n = 128) 0.89 0.80
Post-operative treatment (vs. none)
 Palliative RT (30 Gy) 0.58 0.01
 Radical RT (60 Gy) 0.31 0.003
 Chemotherapy + RT (60 Gy) 0.20 < 10−10
 Repeat resection 1.33 0.21
Fig. 2  Effect on Survival of Residual Enhancing Tumour on MRI. 
Kaplan–Meier survival curves, adjusted for baseline covariates and 
post-operative treatment, for patients with and without evidence of 
residual enhancing tumour on post-operative MRI within 72 h from 
surgery. HR hazard ratio for the log-rank test
Table 3  Comparison of residual fluorescence with residual enhance-
ment on MRI
% Residual MRI 
enhancement
Negative Positive
Residual 5-ALA fluorescence Negative 41.0 23.1
Positive 17.6 18.3
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Accordingly, the fully adjusted survival curves for patients 
who did and did not receive carmustine wafers were similar 
and, within the limits of this study, there did not appear to 
be a marginal effect of carmustine wafers that might emerge 
as statistically or clinically significant in a larger cohort. 
Moreover, carmustine wafers were associated with a ten-
dency to a higher wound complications and infection.
While the implantation of carmustine wafers is an appeal-
ing approach to deliver high local concentrations of chemo-
therapy; they have been shown to provide only limited pen-
etration and degrade over the course of 6–8 weeks [16]. With 
this pharmacokinetic profile, it may be the case that local 
carmustine are effective at the resection margins but have no 
impact on malignant cells penetrating beyond the enhancing 
disease evident on MRI.
The phase III randomised trial by Stummer and col-
leagues showed that 5-ALA guided resection nearly dou-
bled the proportion of patients in whom a complete resection 
was achieved (65 vs. 36%) and this in turn was associated 
with a significant increase in progression-free survival at 
6 months (41.0 vs. 21.1%) [8]. However, the study was 
designed and conducted prior to temozolomide emerging 
as the optimal post-surgical treatment of WHO grade IV 
glioma, and patients allocated to both 5-ALA and control 
groups received radiotherapy only as first line adjuvant ther-
apy, with chemotherapy reserved until tumour recurrence. In 
the phase III trial of radiotherapy compared with combined 
radiotherapy and concomitant and adjuvant temozolomide 
by Stupp et al. there was a significant survival benefit in 
the chemotherapy arm (median 14.6 vs. 12.1 months) [17]. 
Moreover, a post-hoc analysis of the trial data suggested 
that the greatest benefit of the radiotherapy plus temozolo-
mide regimen was in patients with greater tumour resection 
[8]. Together, these trials indicate that improved resection 
directly extends survival and enhances the treatment effect 
of radical chemo-radiotherapy. Both 5-ALA guided surgery 
and temozolomide based chemo-radiotherapy are being 
used increasingly in modern practice with a demonstrated 
increase in overall survival [18].
In contrast to the widespread adoption of fluorescence-
guided surgery and temozolomide-based adjuvant therapy, 
the role of local chemotherapy in the form of implantable 
carmustine wafers has remained controversial. Two ran-
domised controlled trials have assessed the efficacy of car-
mustine wafers inserted at primary surgery for suspected 
malignant glioma [10]. In the initial small study by Valton-
nen et al. randomising 32 patients (27 confirmed as grade 
IV glioma) a significant survival benefit associated with 
carmustine wafers was observed. The subsequent phase III 
study by Westphal et al. enrolled 240 patients and showed 
an overall 2-month improvement in median survival but 
the difference between treatment groups for the subset of 
patients with grade IV glioma was not significant [11]. 
Moreover, in both trials post-operative treatment was again 
limited to radiotherapy alone until tumour recurrence. The 
inconclusive trial findings and the proven efficacy of com-
bined radiotherapy and temozolomide has limited the routine 
adoption of carmustine wafers as a primary therapy. None-
theless, a number of reports have detailed the outcomes of 
multimodal treatment with carmustine wafers followed by 
combined radiotherapy and temozolomide, and in general 
suggest longer median overall survival than observed in 
either the Stupp et al. or Westphal et al. RCTs [19]. However, 
such observational studies are inherently subject to selection 
bias. Further, since the introduction of technologies such as 
5-ALA to maximise tumour resection, the added benefit of 
carmustine wafers has become increasingly unclear.
In our centre, 5-ALA guided tumour resection and radical 
chemoradiotherapy with temozolomide have been the stand-
ard of care since 2009. The proportion of patients in whom 
a complete resection was achieved under 5-ALA guidance 
was similar to that in the original RCT by Stummer et al. 
[8]. The overall outcomes in the present cohort are improved 
over historical data from our unit prior to the introduction of 
5-ALA guided resection and temozolomide chemotherapy 
[20]. Currently we utilise 5-ALA routinely in patients where 
there is intent to resect tumour to its enhancing margin, if 
possible around the entire tumour or restricted to regions 
bordering non-eloquent brain. Intraoperatively, the resec-
tion of fluorescent tumour is judiciously assessed against 
the risk of neurological deficit, incorporating neurophysi-
ological cortical and subcortical mapping and awake testing 
where appropriate [9]. Higher rates of complete resection 
with 5-ALA have been reported in other studies but these 
series are typically highly selected subgroups of patients 
in whom total resection is deemed possible at the outset 
[21–23]. No previous studies have examined the effect of 
carmustine wafers in a treatment programme consisting 
of 5-ALA guided resection followed by a temozolomide-
based chemoradiation: the present findings suggest there is 
no clinically or statistically significant benefit. In the period 
since the cohort in this study were treated we have not used 
carmustine wafers at primary resection of grade IV glioma.
Post-hoc analyses of several trial and data from many 
retrospective studies support the crucial value of surgi-
cal resection and debate the optimal volume of tumour to 
be removed [24]. Three Cochrane Reviews together with 
systematic reviews by the European Society for Medical 
Oncology (ESMO) and the European Association of Neuro-
Oncology (EANO) highlight the importance of surgery [2, 
3, 25–27]. More recently, compelling prospective data has 
begun to emerge showing that complete resection confers 
a survival advantage, although formal prospective data is 
lacking. A meta-analysis of three randomized phase III trials 
that recruited a total of 1056 patients concluded, “complete 
resection appears to improve survival and may increase the 
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efficacy of adjunct/adjuvant therapies” [28]. A prospective 
clinical trial of 60 grade IV glioma patients showed lack of 
efficacy of enzastaurin (a PKC and PI-3 kinase/Akt inhibi-
tor) but a secondary analysis revealed a strong prognostic 
influence of resection on overall survival [29]. A prospec-
tive surgical cohort study of 143 grade IV glioma patients 
showed that the best clinical outcomes were described in 
those who had complete resection of enhancing disease 
(median survival for those without residual disease exceeded 
24 months, was 16.9 months for those with residual tumour 
diameter > 0 to ≤ 1 and 13.9 months for those with > 1.5 cm 
residual disease) and concluded that completeness of resec-
tion acts synergistically with radiochemotherapy [4]. A pro-
spective multicenter study of 345 grade IV glioma patients 
identified GTR as a prognostic factor in multivariate analy-
sis (HR = 0,60; P = 0.003) for overall survival with those 
undergoing incomplete resection doing no better than those 
receiving biopsy only [5]. Finally, a retrospective review 
of 692 patients in the AVAglio trial reported “post-surgical 
residual enhancing tumor volume is prognostic for OS in 
newly diagnosed grade IV glioma patients” [30]. Residual 
tumour identified by intraoperative 5-ALA fluorescence has 
also been shown to be an independent prognostic indicator 
in patients with no remaining enhancing disease on MRI 
[21]. Findings in the present study are consistent with these 
previous reports: both residual fluorescence at completion of 
surgery and residual enhancing tumour on MRI were inde-
pendently associated with reduced survival. When adjusted 
for other factors, evidence of complete resection on early 
post-operative MRI extended median survival by approxi-
mately 3 months.
The impact of residual enhancing tumour on outcome 
raises the question of whether early reoperation to complete 
the resection would be beneficial in selected patients. More 
research is needed to characterise the volume and patterns 
of residual tumour on MRI to assess the safety of such an 
approach i.e. differentiating ‘missed’ and resectable tumour 
from disease infiltrating eloquent brain with high likelihood 
of causing neurological deficit. Resecting small volumes of 
residual tumour may be challenging in the early post-oper-
ative setting: anatomical landmarks will be distorted and 
neuronavigation systems may be less accurate due to brain 
shift. In addition, the lack of concordance between residual 
5-ALA fluorescence and residual on MRI in a minority of 
patients requires further investigation to determine if there 
is genuinely enhancing tumour that does not take up 5-ALA 
or fluorescent disease that does not enhance. A multimodal 
approach using a combination of technologies to guide 
resection, including 5-ALA and others such as intraopera-
tive MRI, may offer the best prospect of achieving complete 
tumour resection [22].
The principal limitation of the present study is its retro-
spective nature. The propensity score matching technique 
was employed to mitigate, as best as possible, selection bias 
and adjust for imbalance in baseline and pre-implantation 
variables. This procedure extracts matched subgroups of 
patients and provides the best available approximation to 
the balanced groups that would be expected in a hypotheti-
cal randomised controlled trial allocating patients to receive 
5-ALA guided resection with or without the addition of car-
mustine wafers. The study represents a real-life cohort of 
neuro-oncology patients; patient selection was not limited to 
those who received chemo-radiotherapy, reflecting that some 
patients may not be fit enough for further treatment after 
surgery. In addition, there was incomplete data for molecu-
lar characterisation of all patients in the study and the lack 
of association between MGMT methylation and survival is 
difficult to interpret. Variability within and between assays, 
and controversy around promotor methylation and protein 
expression are well recognised [31]. Several studies have 
reported a lack of correlation between MGMT promotor 
methylation status and clinical outcome [32–36] including 
a clinical trial [34] and a prospective cohort study [35].
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